Albireo Pharma Analysis

Summary

ALBODelisted Stock

USD 44.15 0.75 1.67%

The recent price roll up of Albireo Pharma could raise concerns from insiders as the firm is trading at a share price of 44.15 on very low momentum in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in April. The stock standard deviation of daily returns for 90 days investing horizon is currently 14.07. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Albireo Pharma partners.

Check out Trending Equities.

The main objective of Albireo Pharma stock analysis is to determine its intrinsic value, which is an estimate of what Albireo Pharma is worth, separate from its market price. There are two main types of Albireo Pharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Albireo Pharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Albireo Pharma's stock to identify patterns and trends that may indicate its future price movements.

Total Assets Total Debt

The Albireo Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Albireo Pharma is usually not traded on Thanksgiving Day, Christmas Day, Christmas Day ( substitute day ), New Year 's Monday, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Albireo Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Albireo Pharma's ongoing operational relationships across important fundamental and technical indicators.

Albireo Stock Analysis Notes

About 96.0% of the company shares are held by institutions such as insurance companies. The book value of Albireo Pharma was presently reported as 4.84. The company recorded a loss per share of 6.66. Albireo Pharma last dividend was issued on the 4th of November 2016. The entity had 1:30 split on the 4th of November 2016. Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. Albireo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 130 people. For more info on Albireo Pharma please contact Ronald Cooper at 857 254 5555 or go to https://www.albireopharma.com.

Albireo Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Albireo Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Albireo Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.

	Albireo Pharma is not yet fully synchronised with the market data
	Albireo Pharma is way too risky over 90 days horizon
	Albireo Pharma appears to be risky and price may revert if volatility continues
	Albireo Pharma has a very high chance of going through financial distress in the upcoming years
	Albireo Pharma was previously known as ALBIREO PHARMA INC and was traded on NASDAQ Exchange under the symbol BIOD.
	The company reported the previous year's revenue of 40.58 M. Net Loss for the year was (34.03 M) with profit before overhead, payroll, taxes, and interest of 39.22 M.
	Albireo Pharma currently holds about 180.97 M in cash with (107.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.23.
	Albireo Pharma has a frail financial position based on the latest SEC disclosures
	Over 96.0% of the company shares are held by institutions such as insurance companies

Albireo Pharma Upcoming and Recent Events

Earnings reports are used by Albireo Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Albireo Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	7th of March 2023 Upcoming Quarterly Report	View
	15th of May 2023 Next Financial Report	View
	31st of December 2022 Next Fiscal Quarter End	View
	7th of March 2023 Next Fiscal Year End	View
	30th of September 2022 Last Quarter Report	View
	31st of December 2021 Last Financial Announcement	View

Albireo Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Albireo Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Albireo Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Albireo Pharma specific information freely available to individual and institutional investors to make a timely investment decision.

	27th of February 2023 Unclassified Corporate Event	View
	24th of February 2023 Unclassified Corporate Event	View
	22nd of February 2023 Unclassified Corporate Event	View
	14th of February 2023 Financial Statements and Exhibits. Other Events. Unclassified Corporate Event	View
	1st of February 2023 Unclassified Corporate Event	View
	31st of January 2023 Unclassified Corporate Event	View
	23rd of January 2023 Unclassified Corporate Event. Unclassified Corporate Event	View
	10th of January 2023 Unclassified Corporate Event	View

Albireo Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 915.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Albireo Pharma's market, we take the total number of its shares issued and multiply it by Albireo Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Albireo Profitablity

Albireo Pharma's profitability indicators refer to fundamental financial ratios that showcase Albireo Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Albireo Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Albireo Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Albireo Pharma's profitability requires more research than a typical breakdown of Albireo Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.

The company has Profit Margin (PM) of (2.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.15.

	Last Reported	Projected for 2023
Return on Investment	(75.44)	(81.40)
Return on Average Assets	(0.15)	(0.15)
Return on Average Equity	(0.25)	(0.27)
Return on Invested Capital	20.74	22.38
Return on Sales	(0.57)	(0.62)

Albireo Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Albireo Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Albireo Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Albireo Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Weisman Scott over three months ago Sale by Weisman Scott of 3851 shares of Albireo Pharma
		Simon Harford over three months ago Sale by Simon Harford of tradable shares of Albireo Pharma
		Pamela Stephenson over six months ago Sale by Pamela Stephenson of 445 shares of Albireo Pharma
		Alesina Susan over six months ago Acquisition by Alesina Susan of 16000 shares of Albireo Pharma subject to Rule 16b-3
		Alesina Susan over six months ago Acquisition by Alesina Susan of 16000 shares of Albireo Pharma subject to Rule 16b-3
		Pamela Stephenson over six months ago Sale by Pamela Stephenson of 106 shares of Albireo Pharma
		Simon Harford over six months ago Sale by Simon Harford of tradable shares of Albireo Pharma
		Pamela Stephenson over six months ago Sale by Pamela Stephenson of 461 shares of Albireo Pharma
		Pamela Stephenson over six months ago Sale by Pamela Stephenson of 103 shares of Albireo Pharma
		Simon Harford over six months ago Sale by Simon Harford of tradable shares of Albireo Pharma
		Pamela Stephenson over a year ago Sale by Pamela Stephenson of 454 shares of Albireo Pharma
		Pamela Stephenson over a year ago Sale by Pamela Stephenson of 416 shares of Albireo Pharma

Albireo Pharma Technical and Predictive Indicators

	Risk Adjusted Performance	0.1306
	Market Risk Adjusted Performance	(1.75)
	Mean Deviation	3.65
	Semi Deviation	1.31
	Downside Deviation	2.24
	Coefficient Of Variation	778.11
	Standard Deviation	11.63
	Variance	135.36
	Information Ratio	0.1278
	Jensen Alpha	1.48
	Total Risk Alpha	1.5
	Sortino Ratio	0.664
	Treynor Ratio	(1.76)
	Maximum Drawdown	92.96
	Value At Risk	(3.00)
	Potential Upside	5.41
	Downside Variance	5.01
	Semi Variance	1.71
	Expected Short fall	(5.49)
	Skewness	7.5
	Kurtosis	59.09

	Risk Adjusted Performance	0.1306
	Market Risk Adjusted Performance	(1.75)
	Mean Deviation	3.65
	Semi Deviation	1.31
	Downside Deviation	2.24
	Coefficient Of Variation	778.11
	Standard Deviation	11.63
	Variance	135.36
	Information Ratio	0.1278
	Jensen Alpha	1.48
	Total Risk Alpha	1.5
	Sortino Ratio	0.664
	Treynor Ratio	(1.76)
	Maximum Drawdown	92.96
	Value At Risk	(3.00)
	Potential Upside	5.41
	Downside Variance	5.01
	Semi Variance	1.71
	Expected Short fall	(5.49)
	Skewness	7.5
	Kurtosis	59.09

About Albireo Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Albireo Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Albireo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Albireo Pharma. By using and applying Albireo Stock analysis, traders can create a robust methodology for identifying Albireo entry and exit points for their positions.

	Last Reported	Projected for 2023
EBITDA Margin	(0.44)	(0.47)
Gross Margin	0.87	0.88
Profit Margin	(0.76)	(0.82)

Current Albireo Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Albireo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Albireo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Target Price	Advice	# of Analysts
47.33	Hold	6	Odds

Albireo Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.

Most Albireo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Albireo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Albireo Pharma, talking to its executives and customers, or listening to Albireo conference calls.

Albireo Analyst Advice Details

Albireo Stock Analysis Indicators

Albireo Pharma stock analysis indicators help investors evaluate how Albireo Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Albireo Pharma shares will generate the highest return on investment. By understating and applying Albireo Pharma stock analysis, traders can identify Albireo Pharma position entry and exit signals to maximize returns.

	Begin Period Cash Flow	251.3 M
	Total Stockholder Equity	175.6 M
	Property Plant And Equipment Net	668 K
	Retained Earnings	-300.9 M
	Cash And Short Term Investments	248.1 M
	Retained Earnings Total Equity	-300.9 M
	Cash	248.1 M
	50 Day M A	37.9726
	Net Interest Income	-13.9 M
	Total Current Liabilities	45.3 M
	Investments	102.9 M
	Common Stock Total Equity	193 K
	Interest Expense	13.9 M
	Stock Based Compensation	15.9 M
	Common Stock Shares Outstanding	19.2 M
	Total Cashflows From Investing Activities	102.9 M
	Accounts Payable	6.5 M
	Net Debt	-238.1 M
	Other Operating Expenses	164.1 M
	Non Current Assets Total	33.1 M
	Liabilities And Stockholders Equity	302.1 M
	Non Currrent Assets Other	15.2 M

Check out Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.

	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Bond Directory Find actively traded corporate debentures issued by US companies
	Price Transformation Use Price Transformation models to analyze depth of different equity instruments across global markets
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC